Nanoform Finland Oyj (HEL:NANOFH)
Finland · Delayed Price · Currency is EUR 1.008
-0.020 (-1.95%)
Jul 18, 2025, 6:29 PM EET
Nanoform Finland Oyj Company Description
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States.
The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and flexible dosage forms of nanoformed drug substances.
It also offers STARMAP, an online platform to pick winners among candidate molecules for CESS powered nanoforming.
The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj
| Country | Finland |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Edward Haeggstrom |
Contact Details
Address: Cultivator II Helsinki, 00790 Finland | |
| Phone | 358 2937 00150 |
| Website | nanoform.com |
Stock Details
| Ticker Symbol | NANOFH |
| Exchange | Nasdaq Helsinki |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FI4000330972 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Prof. Edward Olof Haeggstrom | Co-Founder and Chief Executive Officer |
| Albert Alexander Haeggstrom | Chief Financial Officer and Director |
| Henri von Haartman | Director of Investor Relations |
| Peter Hanninen | General Counsel and Chief Development Officer |
| Dr. David Rowe | Head of Manufacturing |
| Christian Jones | Chief Commercial Officer |
| Antonio Da Silva | Chief of Business Operations |
| Johanna Kause | Chief Quality Officer |
| Dr. Jamie Unwin | Vice President of Strategic Insight |